metricas
covid
Buscar en
Revista de Psiquiatría y Salud Mental (English Edition)
Toda la web
Inicio Revista de Psiquiatría y Salud Mental (English Edition) Impact of the Spanish Consensus on Physical Health of Patients with Schizophreni...
Información de la revista
Vol. 3. Núm. 4.
Páginas 119-127 (enero 2009)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 3. Núm. 4.
Páginas 119-127 (enero 2009)
Acceso a texto completo
Impact of the Spanish Consensus on Physical Health of Patients with Schizophrenia
Impacto del Consenso Español sobre la Salud Física del Paciente con Esquizofrenia
Visitas
1154
Jerónimo Saiz-Ruiza,
Autor para correspondencia
jsaiz.hrc@salud.madrid.org

Corresponding author.
, M. Dolores Saiz-Gonzálezb, Analucía A. Alegríaa,c, Esperanza Menad, Julia Luquee, Julio Bobesf
a Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Hospital Universitario Ramón y Cajal, Departamento de Psiquiatría, Universidad de Alcalá, Madrid, Spain
b Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Hospital Universitario Clínico San Carlos, Departamento de Psiquiatría, Universidad Complutense, Madrid, Spain
c New York State Pychiatric Institute, New York, USA
d Otsuka Pharmaceutical, S.A., Barcelona, Spain
e Bristol Myers Squibb, Departamento Médico, Madrid, Spain
f Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Departamento de Psiquiatría, Universidad de Oviedo, Oviedo, Asturias, Spain
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Abstract
Introduction

This study evaluates the physical health of patients with schizophrenia and analyzes the change in the percentage of patients with evaluations in the known diabetes and cardiovascular risk predictors before and 6 months after the dissemination of the “Consensus on Physical Health in Schizophrenia Patients”.

Material and methods

This is an epidemiological non-interventional and transversal study, in which 229 psychiatrists evaluated 1,193 clinical records of patients with a diagnose of schizophrenia according to ICD-10, attended in the psychiatry consultations planned in January and September of 2007. Study results were analyzed using descriptive statistics.

Results

1,193 evaluable patients were included, with a mean age of 39.7±11.6 years, diagnosed of schizophrenia 15.0±10.3 years ago, and a 65.90% were men. The presence of concomitant diseases was 39.98%, being hypercholesterolemia (46.33%), hypertriglyceridaemia (33.54%) and arterial hypertension (26.00%) the most frequent. After the dissemination of the Consensus, the percentage of patients who had all the physical measurements taken increased by 13.75%. Forty eight per cent of the psychiatrists were considered as being aware of the Consensus. The percentage of measurements taken was higher within the psychiatrists who were aware of the Consensus (17.32%) than within those who were not aware of it (10.33%).

Conclusions

The results of this study show an increase of the physical health control from patients with schizophrenia after the dissemination of the Consensus, which should improve an integral approach of these patients to ensure a similar life expectancy, quality of life and function to the general population.

Keywords:
Schizophrenia
Physical health
Consensus
Resumen
Introducción

Este estudio evalúa la salud física de los pacientes con esquizofrenia y analiza el cambio en el porcentaje de pacientes con evaluaciones en los conocidos predictores de diabetes y riesgo cardiovascular antes y 6 meses después de la difusión del «Consenso Español sobre la Salud Física del Paciente con Esquizofrenia».

Material y métodos

Se trata de un estudio epidemiológico de corte transversal no intervencionista, en que 229 psiquiatras evaluaron 1.193 historias clínicas de pacientes diagnosticados de esquizofrenia según CIE-10, atendidos en las consultas de psiquiatría programadas primero en enero y posteriormente en septiembre de 2007. Los resultados del estudio se analizaron mediante estadística descriptiva.

Resultados

Se incluyeron 1.193 pacientes evaluables, con una edad media de 39,7±11,6 años, diagnosticados de esquizofrenia desde hacía 15,0±10,3 años, y un 65,90% eran hombres. La presencia de enfermedades concomitantes fue del 39,98%, siendo hipercolesterolemia (46,33%), hipertrigliceridemia (33,54%) e hipertensión arterial (26,00%) las más frecuentes. Tras la difusión del Consenso, aumentó en un 13,75% el porcentaje de pacientes a los que se realizaron todas las mediciones de salud física. El 48,5% de los psiquiatras se consideraron conocedores del Consenso. El porcentaje de evaluaciones realizadas fue superior entre los psiquiatras conocedores del Consenso (17,32%) que entre aquellos que no lo conocían (10,33%).

Conclusiones

Los resultados de este estudio muestran un aumento del control de la salud física de los pacientes con esquizofrenia tras la difusión del Consenso, que mejoraría el abordaje integral de estos pacientes para garantizar una esperanza de vida, calidad de vida y funcionamiento similares a los de la población general.

Palabras clave:
Esquizofrenia
Salud física
Consenso
El Texto completo está disponible en PDF
References
[1.]
D. Bhugra.
The global prevalence of schizophrenia.
PLoS Med, 2 (2006), pp. 372-373
[2.]
E.M. Goldner, L. Hsu, P. Waraich, J.M. Somers.
Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature.
Can J Psychiatry, 47 (2002), pp. 833-843
[3.]
A. Jablensky, N. Sartorius, G. Ernberg, M. Anker, A. Korten, J.E. Cooper, et al.
Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study.
Psychol Med Monogr Suppl, 30 (1992), pp. 1-97
[4.]
D. Castle, S. Wesseley, G. Der, R.M. Murray.
The incidence of operationally defined schizophrenia in Camberwell 1965–84.
Br J Psychiatry, 159 (1991), pp. 790-794
[5.]
C.M. Valencia.
Trastornos mentales y problemas de salud mental: Día mundial de la salud mental 2007.
Salud Ment, 30 (2007), pp. 75-80
[6.]
D.C. Goff, C. Cather, A.E. Evins, D.C. Henderson, O. Freudenreich, P.M. Copeland, et al.
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.
J Clin Psychiatry, 66 (2005), pp. 183-194
[7.]
Y. Von Hausswolff-Juhlin, M. Bjartveit, E. Lindström, P. Jones.
Schizophrenia and physical health problems.
Acta Psychiatr Scand Suppl, 438 (2009), pp. 15-21
[8.]
S. Brown, H. Inskip, B. Barraclough.
Causes of the excess mortality of schizophrenia.
Br J Psychiatry, 177 (2000), pp. 212-217
[9.]
J. Bobes, C. Arango, P. Aranda, R. Carmena, M. García-García, J. Rejas.
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS study.
Schizophr Res, 90 (2007), pp. 162-173
[10.]
C. Arango, J. Bobes, P. Aranda, R. Carmena, M. García-García, J. Rejas, et al.
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study.
Schizophr Res, 104 (2008), pp. 1-12
[11.]
T. Cohn, D. Prud’homme, D. Streiner, H. Kameh, G. Remington.
Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.
Can J Psychiatry, 49 (2004), pp. 753-760
[12.]
J. Sáiz Ruiz, J. Bobes García, J. Vallejo Ruiloba, J. Giner Ubago, M.P. García-Portilla González, Grupo de Trabajo sobre la Salud Física del Paciente con Esquizofrenia.
Consenso sobre la salud física del paciente con esquizofrenia de las Sociedades Españolas de Psiquiatría y de Psiquiatría Biológica.
Actas Esp Psiquiatr, 36 (2008), pp. 251-264
[13.]
J. Lybrand, S. Caroff.
Management of schizophrenia with substance use disorders.
Psychiatr Clin North Am, 32 (2009), pp. 821-833
[14.]
H. Häfner.
Psychosis and Cannabis.
Rev Psiq Clin, 32 (2005), pp. 53-67
[15.]
R. Filik, A. Sipos, P.G. Kehoe, T. Burns, S.J. Cooper, H. Stevens, et al.
The cardiovascular and respiratory Elath of people with schizophrenia.
Acta Psychiatr Scand, 113 (2006), pp. 298-305
[16.]
T.P. George, J.C. Vessicchio, A. Termine, T.A. Bregartner, A. Feingold, B.J. Rounsaville, et al.
A placebo controlled trial of bupropion for smoking cessation in schizophrenia.
Biol Psychiatry, 52 (2002), pp. 53-61
[17.]
E.C. Harris, B. Barraclough.
Excess mortality of mental disorders.
Br J Psychiatry, 173 (1998), pp. 11-53
[18.]
C.H. Hennekens, A.R. Hennekens, D. Hollar, D.E. Casey.
Schizophrenia and increased risks of cardiovascular disease.
Am Heart J, 150 (2005), pp. 1115-1121
[19.]
C. Enger, L. Weatherby, R.F. Reynolds, D.B. Glasser, A.M. Walker.
Serious cardiovascular events and mortality among patients with schizophrenia.
J Nerv Ment Dis, 192 (2004), pp. 19-27
[20.]
S.M. Curkendall, J. Mo, D.B. Glasser, M. Rose Stang, J.K. Jones.
Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.
J Clin Psychiatry, 65 (2004), pp. 715-720
[21.]
L. Friedli, C. Dardis.
Not all in the mind: Mental health service user perspectives on physical health.
J Mental Health Promotion, 1 (2002), pp. 36-46
[22.]
M. De Hert, J.M. Dekker, D. Wood, K.G. Kahl, R.I. Holt, H.J. Möller.
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC).
Eur Psychiatry, 24 (2009), pp. 412-424
[23.]
H.A. Nasrallah.
An overview of common medical comorbidities in patients with schizophrenia.
J Clin Psychiatry, 66 (2005), pp. 3-4
[24.]
C. Bushe, P. Haddad, R. Peveler, J. Pendlebury.
The role of lifestyle interventions and weight Management in schizophrenia.
J Psychopharmacol, 19 (2005), pp. 28-35
[25.]
Y. Nakamura, M. Koh, E. Miyoshi, O. Ida, M. Morikawa, A. Tokuyama, et al.
High prevalence of the hepatitis C virus infection among the inpatients of schizophrenia and psychoactive substance abuse in Japan.
Prog Neuropsychopharmacol Biol Psychiatry, 28 (2004), pp. 591-597
[26.]
L. Grassi, M. Pavanati, R. Cardelli, S. Ferri, L. Peron.
HIV-risk behaviour and knowledge about HIV/AIDS among patients with schizophrenia.
Psychol Med, 29 (1999), pp. 171-179
[27.]
M.B. Blank, D.S. Mandell, L. Aiken, T.R. Hadley.
Co-ocurrence of HIV and serious mental illness among medicaid recipients.
Psychiatr Serv, 53 (2002), pp. 868-873
[28.]
M. Subramaniam, S.A. Chong, E. Pek.
Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia.
Can J Psychiatry, 48 (2003), pp. 345-347
[29.]
C. Carlson, K. Hornbuckle, F. DeLisle, L. Kryzhanovskaya, A. Breier, P. Cavazzoni.
Diabetes mellitus and antipsychotic treatment in the United Kingdom.
Eur Neuropsychopharmacol, 16 (2006), pp. 366-375
[30.]
J.B. Buse, P. Cavazzoni, K. Hornbuckle, D. Hutchins, A. Breier, L. Jovanovic.
A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States.
J Clin Epidemiol, 56 (2003), pp. 164-170
[31.]
T. Heiskanen, L. Niskanen, R. Lyytikainen, P.I. Saarinen, J. Hintikka.
Metabolic syndrome in patients with schizophrenia.
J Clin Psychiatry, 64 (2003), pp. 575-579
[32.]
M.A. De Hert, R. Van Winkel, D. Van Eyck, L. Hanssens, M. Wampers, A. Scheen, et al.
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.
Schizophr Res, 83 (2006), pp. 87-93
[33.]
S. Brown.
Excess mortality of schizophrenia. A meta-analysis.
Br J Psychiatry, 171 (1997), pp. 502-508
[34.]
U. Osby, N. Correia, L. Brandt, A. Ekbom, P. Sparén.
Mortality and causes of death in schizophrenia in Stockholm County Sweden.
Schizophrenia Res, 45 (2000), pp. 21-28
Copyright © 2010. SEP y SEPB
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.rpsmen.2022.01.003
No mostrar más